Trifluoroacetic acid → HCID 118379997, compound
Reaction equation
[N:1]1([CH2:6][C@@H:7]2[C@H:10]([NH:11][C:12](=[O:38])/[C:13](=[N:27]\[O:28][C@@H:29]([CH3:37])[C:30]([O:32]C(C)(C)C)=[O:31])/[C:14]3[N:15]=[C:16]([NH:19]C(OC(C)(C)C)=O)[S:17][CH:18]=3)[C:9](=[O:39])[N:8]2[S:40]([OH:43])(=[O:42])=[O:41])[CH:5]=[N:4][CH:3]=[N:2]1.C(O)(C(F)(F)F)=O>C(Cl)Cl>[N:1]1([CH2:6][C@@H:7]2[C@H:10]([NH:11][C:12](=[O:38])/[C:13](=[N:27]\[O:28][C@@H:29]([CH3:37])[C:30]([OH:32])=[O:31])/[C:14]3[N:15]=[C:16]([NH2:19])[S:17][CH:18]=3)[C:9](=[O:39])[N:8]2[S:40]([OH:43])(=[O:41])=[O:42])[CH:5]=[N:4][CH:3]=[N:2]1Participants
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Procedure
Followed the general procedure for the acid mediated deprotection using (2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-3-((Z)-2-((((S)-1-(tert-butoxy)-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoazetidine-1-sulfonic acid (23 mg, 0.036 mmol), DCM (357 μL) and TFA (165 μL, 2.14 mmol). The crude residue was purified by reverse phase prep HPLC (XSelect CSH, 19×100 mm, 5 μm, C18 column; ACN-water with 0.1% formic acid modifier, 24 mL/min), affording the title compound (7.9 mg, 36%) as a white powder. LCMS: Rt=0.40 min, m/z=489.0 (M+1) Method 2m_acidic_polar; 1H NMR (400 MHz, D2O) δ 8.69 (s, 1H), 8.18 (s, 1H), 7.20 (s, 1H), 5.54 (d, J=5.7 Hz, 1H), 4.96-4.67 (m, 4H assumed; partially obscured by solvent residual peak), 1.44 (d, J=7.0 Hz, 3H).
Workup
- customThe crude residue was purified by reverse phase prep HPLC (XSelect CSH, 19×100 mm, 5 μm, C18 column; ACN-water with 0.1% formic acid modifier, 24 mL/min)
Sources & evidence
- ORD record
- ord-c2728e5c10854fb3bdf1e2210ffadce3
- Source dataset
- uspto-grants-2015_11
- Patent number
- US09174978B2
Reaction notes
Loading…